Humacyte terminates $80M at-the-market offering agreement with Jefferies

Humacyte, Inc.

Agreement allowed sale of up to $80M in common stock via Jefferies as agent.
Termination notice delivered November 21, 2025; effective 10 days later.
Company is not subject to any termination penalties.
No new financing or replacement agreement announced.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Humacyte, Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at up to $80,000,000 (effective 2025-11-21).

Action: termination
Agreement: equity purchase
Counterparty: Jefferies LLC
Value: up to $80,000,000
Effective: 2025-11-21

Exact text from the filing

On November 21, 2025, the Company delivered a notice to Jefferies terminating the Agreement, which termination will become effective under the Agreement 10 days thereafter.

View on SEC.gov

Browse all material agreements →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-116476

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.